Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalBlue Cross Blue Shield SD Artificial Disc Coverage…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - south dakotaPolicy N/A

    Artificial Intervertebral Disc (Cervical and Lumbar) Coverage Criteria

    Customize your policy alerts

    Sign up for all blue cross blue shield - south dakota policy alerts

    Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, investigational indications, documentation, and device-level approvals for cervical and lumbar artificial intervertebral disc implantation for Blue Cross Blue Shield - South Dakota members.

    Policy Summary
    Payerblue cross blue shield - south dakota
    PolicyArtificial Intervertebral Disc (Cervical and Lumbar) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateFeb 1, 2005
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with surgeon evaluation, documentation of failed conservative therapy, imaging, and device FDA-approval for planned level(s).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1-2 levelsFDA-approved cervical disc indications discussed
    single-levelLumbar single-level considered
    6+ monthsLumbar conservative duration
    6 weeksCervical conservative duration
    T-score <1.0Osteopenia contraindication (T-score)
    64.9%–83.8%Reported overall success range

    Coverage and Medical Necessity Criteria

    inv-01: Cervical Artificial Disc: Initial — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cervical initial criteria: Is skeletally mature
    Cervical initial criteria: Has intractable cervical radicular pain or myelopathy
    Cervical initial criteria: Has failed at least 6 weeks of conservative nonoperative treatment that includes an active pain management program with appropriate pharmacotherapy (including agents addressing neuropathic pain) and physical therapy; exceptions allowed for severe or rapidly progressive neurologic compression or documented contraindication to physical therapy>= 6 weeks

    See device labeling for exceptions

    Policy Summary
    Payerblue cross blue shield - south dakota
    PolicyArtificial Intervertebral Disc (Cervical and Lumbar) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateFeb 1, 2005
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization with surgeon evaluation, documentation of failed conservative therapy, imaging, and device FDA-approval for planned level(s).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure and Device CodingPreauthorization, Documentation, and Operational RequirementsClinical Background and Evidence SummaryKey Definitions and MeasuresPolicy History and References
    Cervical initial criteria: Degeneration documented from C3 through C7 by x-ray, MRI, CT, or myelography
    Cervical initial criteria: Nerve root and/or cord compression due to herniated disc and/or spondylosis
    Cervical initial criteria: Proposed implant is FDA-approved for the intended vertebral level(s) and will be used at the number of levels permitted by the device approval

    Each device may have device-specific contraindications

    Cervical initial criteria: Individual is free from device-specific FDA contraindications as identified on the device label

    See investigational/contraindication lists for examples

    inv-02: Two-Level Cervical Artificial Disc — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Two-level cervical criteria: All initial cervical artificial disc criteria (per single-level) are met for each disc level
    Two-level cervical criteria: Proposed implant is FDA-approved for two contiguous levels

    See device-specific PMA/labeling

    Two-level cervical criteria: Procedure is performed at two contiguous levels simultaneously or at a second contiguous level after a prior arthroplasty when the initial implantation is fully healed

    inv-03: Cervical Artificial Disc: Revision — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cervical revision: Imaging confirms failure of the implanted cervical artificial disc (examples: loosening, dislodgement, fracture, or discitis/infection)

    inv-04: Lumbar Artificial Disc: Initial — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Lumbar initial criteria: Age between 18 and 60 years18-60
    Lumbar initial criteria: Chronic, unremitting, severe axial low back pain determined to be of discogenic origin
    Lumbar initial criteria: Moderate to severe single-level degenerative disc disease confirmed by x-ray, MRI, or CTsingle level

    Device-specific allowed levels apply

    Lumbar initial criteria: Clinically significant functional impairment affecting activities of daily living
    Lumbar initial criteria: Failed at least 6 months of consistent nonoperative treatment including an active pain management program with pharmacotherapy and formal physical therapy>= 6 months
    Lumbar initial criteria: Absence of untreated significant mental or behavioral health disorders (e.g., major depression, chronic pain syndrome, opioid or alcohol use disorders)
    Lumbar initial criteria: Proposed device is FDA-approved and will be inserted at the single level and vertebral level(s) approved for that implant

    See device PMA/labeling

    Lumbar initial criteria: Individual is free from device-specific FDA contraindications identified on the device label

    See investigational/contraindication lists for examples

    inv-05: Lumbar Artificial Disc: Revision — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Lumbar revision: Imaging confirms failure of the implanted lumbar artificial disc (examples: loosening, dislodgement, fracture, or discitis/infection)

    inv-06: Coverage criteria for artificial disc replacement — Covered when ALL of the following are met (device-specific labeling applies)

    Covered when ALL of the following are met (device-specific labeling applies):

    Clinical indication: Patient has symptomatic degenerative disc disease (cervical: radiculopathy or myelopathy; lumbar: discogenic back pain) with correlated imaging findings

    Per device labeling; see imaging confirmation requirements in device PMA summaries

    Conservative therapy failure: Failure of appropriate conservative treatment for the duration specified by device labeling (commonly ≥6 weeks for cervical devices; commonly ≥6 months for lumbar devices)see device labeling (>=6 weeks cervical; >=6 months lumbar)

    Progressive neurologic decline may alter timing per labeling

    Anatomic/degenerative limitations: Disease limited to the number of levels appropriate for the device (e.g., single level or up to two contiguous levels per device) and without contraindicating multilevel disease, significant spondylolisthesis, spinal stenosis requiring decompression, or prior major surgery at the treated level unless specifically allowed by labeling

    Device-specific allowed levels listed in regulatory tables

    Contraindications: No tobacco use within the previous 4 weeks and absence of other device-specific contraindications (examples: severe spondylosis/instability, active infection, allergy to implant materials)4 weeks

    Tobacco use is listed as a contraindication in policy text

    inv-07: Medical necessity criteria for artificial intervertebral disc implantation — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Patient selection: Patient is skeletally mature with symptomatic degenerative disc disease at levels indicated for the device; DDD is confirmed by history and radiographic studies

    Device-specific level indications apply

    Prior conservative therapy: Patient has failed an adequate trial of conservative therapy (device approvals and trials commonly required >=6 months or at least 6 weeks of nonoperative care prior to surgery)>=6 months typical (device/trial dependent)

    Trial duration may vary by device/trial entry criteria

    Anatomic/instability limits: Spondylolisthesis and instability are limited per device labeling (examples: Charite ≤3 mm; ProDisc-L ≤ Grade 1)<=3 mm or Grade 1

    Adhere to device-specific contraindications

    Device and level compatibility: Proposed device is FDA-approved for the vertebral level(s) to be treated (examples: ActivL L4-S1; ProDisc-L L3-S1 single or two contiguous levels)

    Thoracic-level disc arthroplasty has no FDA-approved devices

    inv-08: Trial-defined success endpoints — Clinical trial inclusion/efficacy endpoints reported (trial-based criteria and outcomes)

    Clinical trial inclusion/efficacy endpoints reported (trial-based criteria and outcomes):

    FDA trial success endpoints: Improvement in Neck Disability Index (NDI) >15 points, maintenance or improvement in neurologic function, and absence of serious device- or procedure-related adverse events or supplemental surgical proceduresNDI >15 pts

    Endpoint used in FDA SSED summaries

    inv-09: Evidence-based coverage considerations — Clinical trial evidence summary relevant to coverage assessments

    Clinical trial evidence summary relevant to coverage assessments:

    Pivotal trial outcomes: At 2-year follow-up, pivotal trials of multiple cervical artificial discs met noninferiority criteria versus ACDF, with some devices achieving statistical superiority; mid-term (3–7 year) outcomes remain consistent with noninferiority and some trials report lower cumulative reoperation rates

    Summarizes pivotal trial findings

    Long-term evidence: Longer-term outcomes include up to 20-year follow-up for the Bryan cervical disc showing maintained clinical improvements and lower reoperation rates in that randomized cohort; other devices have published outcomes up to 10 years

    Device-specific long-term data vary

    inv-10: General medical necessity considerations — Coverage considerations informed by evidence summarized in this section

    Coverage considerations informed by evidence summarized in this section

    General coverage logic: Patient has degenerative disc disease confirmed by history and radiographs; implantation is of an FDA-cleared artificial disc used per device-specific approvals; conservative treatments were attempted as appropriate; expected benefits include improved pain and function (measured by ODI/VAS/NDI) and potential reduction in adjacent-level degeneration compared with fusion; device and patient selection should align with pivotal trial and FDA inclusion/exclusion criteria; documentation of baseline disability and prior treatments is required

    Synthesis of clinical context and device notes

    inv-11: Cervical (including 2-level) criteria — Cervical 2-level specific considerations

    Cervical 2-level specific considerations

    Cervical 2-level evidence: FDA approvals exist for certain devices for implantation at 2 contiguous levels based on noninferiority or superiority to 2-level ACDF in pivotal trials; reported outcomes include overall success, NDI, reoperation rates, and longer-term follow-up up to 10 years for some devices

    See device-specific approvals and trial summaries

    inv-12: Safety and registry evidence — Key safety and longer-term outcome considerations

    Key safety and longer-term outcome considerations

    Adverse events and registry findings: Heterotopic ossification is common (pooled prevalence ~58% any HO at 24 months; advanced HO ~16.7%); clinically relevant HO is present in a substantial minority at longer follow-up and may have small effects on NDI and neck pain; registry data show small differences favoring CDA for some outcomes but are limited by selection bias and study quality

    Summarizes registry and adverse event data

    inv-13: Evidence-based eligibility features — Coverage-relevant evidence and typical trial-based eligibility features (not an explicit policy decision in this excerpt)

    Coverage-relevant evidence and typical trial-based eligibility features (not an explicit policy decision in this excerpt):

    Trial-based eligibility features: Patient has symptomatic degenerative disc disease at the index level(s) documented radiographically (examples: reduced disc height, Modic changes, posterior high-intensity zone) AND has failed conservative management (commonly ≥6 months for lumbar trials) AND baseline disability reaching trial thresholds (ODI ≥30–40 in some trials) AND absence of exclusion conditions commonly excluded from trials (scoliosis, spondylolisthesis beyond allowed grade, instability, predominant radiculopathy),see trial criteria (eg ODI >=30–40; >=6 months conservative therapy)

    Derived from pivotal trial inclusion/exclusion features

    inv-14: Not established as improving net health outcome — Summary of evidence and coverage stance for lumbar artificial discs

    Covered when ALL of the following are met:

    Primary conclusion: Evidence is insufficient to determine that lumbar artificial intervertebral disc technology results in an improvement in the net health outcome

    RCTs limited by lack of blinding, insufficient long-term follow-up, and limited comparisons for some devices (eg, activL)

    inv-15: Hybrid surgery: no evidence identified — Hybrid surgery (artificial disc combined with fusion)

    Covered when ALL of the following are met:

    Hybrid surgery evidence: No randomized controlled trials or systematic reviews identified evaluating lumbar artificial discs used in hybrid surgery for lumbar degenerative disc disease

    No evidence that hybrid use improves health outcomes

    inv-16: Cervical disc replacement — supported with specified selection — Coverage stance and selection considerations reflected in cited society and guideline input

    Covered when ALL of the following are met:

    Cervical ADR stance: Cervical disc replacement may be medically necessary in appropriately selected patients; evidence shows short-term efficacy comparable to fusion and some longer-term data support use

    Supported by multiple randomized trials and guideline input

    inv-17: Lumbar disc replacement — criteria and exclusions — Lumbar ADR — conditional/limited indications per guideline input

    Covered when ALL of the following are met:

    Lumbar ADR candidate criteria (per NASS/NICE): Patient has symptomatic single-level lumbar disc disease at L3-L4, L4-L5, or L5-S1 with symptoms for ≥6 months unresponsive to multimodal nonoperative treatment (including physical therapy/rehabilitation); primary complaint is axial back pain (possible secondary leg pain); psychiatric disorders must be diagnosed and optimized prior to surgery

    NASS guidance summarized

    Lumbar ADR absolute exclusions (per NASS): One or more of the following: multilevel symptomatic degenerative disk disease; spinal instability with spondylolisthesis > Grade I; chronic predominant radiculopathy (>1 year); osteopenia with DEXA T-score ≤ -1.0; poorly managed psychiatric disorder; significant facet arthropathy at index level; age >60 or <18; infection or tumor

    If any present, ADR is not indicated

    The policy lists multiple investigational or contraindicated conditions for cervical and lumbar artificial disc implantation. Notable exclusions include active infection, allergy or sensitivity to implant materials, and any FDA off‑label utilization. Metabolic or bone health contraindications include osteopenia/osteoporosis with a DEXA T‑score <1.0. Other device‑ or anatomy‑based contraindications include significant anatomic deformity (e.g., ankylosing spondylitis), facet arthritis, malignancy, and autoimmune disease (eg, rheumatoid arthritis). Prior surgery at the target level or prior fusion at another cervical or lumbar level also excludes candidacy per the investigational lists.

    The investigational sections additionally identify procedure‑related exclusions relevant to device use: planned implantation at more than two cervical levels or more than one lumbar level is listed among contraindications, as is combined use of a prosthesis with fusion or another stabilizing procedure (a hybrid construct). These investigational/contraindicated conditions are cited as reasons the technology is considered investigational when present.

    Patients who require additional decompressive procedures (for example, laminectomy or other interventions beyond discectomy and disc reconstruction) or who have multilevel degenerative disease are not considered appropriate candidates for artificial disc implantation. The policy identifies multilevel disease, significant scoliosis, prior major spine surgery, and neurologic symptoms inconsistent with device labeling as exclusions from candidate selection.

    Similarly, lumbar investigational criteria specify imaging‑based exclusions such as moderate or greater bony lumbar spinal stenosis, multilevel degenerative disc disease (≥2 levels), and significant spondylolisthesis or pars defects; such findings indicate the patient may require additional procedures or fusion rather than disc arthroplasty.

    The policy states that devices for thoracic-level disc arthroplasty have not been approved by the FDA. Implantation at thoracic levels is therefore outside FDA‑approved indications and is not supported by the device approvals summarized in this document.

    Within the provided text segments there are no explicit standalone coverage exclusion statements; investigational and contraindication lists and device‑specific labeling language serve to identify scenarios that are unsupported or investigational, but an explicit separate exclusion section is not present in these chunks.

    The Hayes Health Technology Assessment (2017; reviewed 2021) rated 2‑level total disc replacement for cervical DDD as a ‘C’ — characterized as a potential but unproven benefit. The HTA indicates uncertainty remains regarding safety and impact on health outcomes due to study quality, sparse or conflicting data, and other concerns.

    Hayes HTA also evaluated multilevel total disc replacement and hybrid surgery for cervical DDD and rated these uses ‘D2’ (insufficient evidence). The assessment found low‑quality evidence and no consistent between‑group differences, concluding that evidence is insufficient to assess safety or impact on health outcomes for multilevel or hybrid approaches.

    Key pivotal randomized trials generally excluded patients with significant spinal deformity or neurologic conditions. The policy notes that individuals with scoliosis, spondylolisthesis, instability, or radiculopathy were excluded from the pivotal lumbar trials and therefore were not represented in the trial‑supported populations.

    Some pivotal trials had limitations in their comparators and generalizability. The ProDisc‑L two‑level trial and other IDE studies sometimes used comparators that were not the current standard or lacked direct comparison to fusion or conservative care; such comparator limitations reduce the applicability of trial results to routine coverage decisions.

    The North American Spine Society guidance and device labeling summarized in the policy indicate that lumbar artificial disc replacement is not indicated for multilevel symptomatic degenerative disc disease, for spondylolisthesis greater than Grade I, or for chronic preponderant radiculopathy. These device‑ and guideline‑based statements support restricting lumbar ADR to appropriately selected single‑level patients.

    This segment of the document provides coding references and supporting citations but does not present additional explicit coverage criteria or exclusions. Clinical coverage rules and exclusions are described elsewhere in the policy text and investigational lists.

    The policy states that any use that does not meet the listed coverage criteria or that falls under the investigational sections (for example, FDA off‑label use or use of non‑FDA‑approved devices) is considered investigational or not medically necessary. This principle is used to indicate that procedures performed outside device labeling, trial eligibility, or stated contraindication lists will generally be unsupported for routine coverage.

    Examples called investigational include combined prosthesis and fusion (hybrid constructs), implantation of non‑FDA‑approved prostheses, and use in patients with active infection or other contraindications specified in the investigational lists.

    The policy discourages use of artificial discs in patients with contraindicating conditions identified in the investigational lists — specifically multilevel disease beyond device indication, significant spinal stenosis requiring decompression, and spondylolisthesis or other instability beyond device limits. These conditions either preclude adequate device function or indicate that fusion or decompression is a more appropriate surgical strategy.

    Where imaging demonstrates exclusionary findings (e.g., multilevel degenerative disease, moderate or greater facet arthropathy, significant scoliosis), the candidate should not be considered appropriate for ADR per the policy statements.

    The document lists several artificial lumbar devices that are not currently approved or marketed in the U.S. (for example, FlexiCore, INMOTION, Kineflex‑L, Maverick) and emphasizes that thoracic‑level devices have no FDA approvals. Use of devices that are not FDA‑approved or not marketed in the U.S. is not supported for routine coverage and would be considered investigational.

    Examples of currently marketed lumbar devices with FDA approval (ProDisc‑L, ActivL) are distinguished from devices that completed IDE trials or are withdrawn; device regulatory status must be confirmed prior to considering coverage.

    Within the provided excerpts there are no explicit statements that label particular indications as ‘not medically necessary’ in a separate template phrase. Instead, the policy uses investigational lists and device labeling constraints to identify unsupported uses and indicates that uses not meeting criteria are investigational/not medically necessary elsewhere in the policy.

    The provided text does not enumerate a discrete list of specific conditions labeled not medically necessary in this excerpt. However, elsewhere the policy equates uses outside the coverage criteria and investigational lists (such as non‑FDA‑approved devices or off‑label implantations) with investigational or not‑medically‑necessary status.

    Long‑term durability concerns are emphasized for lumbar artificial discs. The policy highlights uncertainty about polyethylene wear debris, the lifespan of prostheses, and the technical complexity and risk of surgical revision, all of which contribute to uncertainty about long‑term outcomes.

    These durability and revision concerns underpin caution in expanding routine use beyond the specific, trial‑eligible populations and contribute to the policy’s position that evidence is insufficient to demonstrate improved net health outcomes for some lumbar devices.

    The policy explicitly states that activL artificial disc use is not supported by randomized controlled trial evidence demonstrating a net health benefit compared with spinal fusion or conservative care. Absence of RCT comparisons to fusion or conservative therapy for activL is cited as a basis for insufficient evidence regarding net health outcome.

    Historically, lumbar artificial discs have been considered investigational in part because randomized controlled trials were limited and concerns remained about long‑term implant complications. External clinical input in 2008 reflected disagreement about investigational labeling, but the policy retained a cautious stance due to trial limitations and unresolved safety and durability questions.

    This excerpt does not present an explicit labeled list stating ‘not medically necessary’ for specific conditions. The policy instead uses investigational lists, device labeling, and trial eligibility constraints to identify uses that are unsupported or investigational.

    Procedure and Device Coding

    Codes table (referenced)mixed
    No codes listed
    Devices (FDA approved and not currently marketed)mixed
    ActivL (device)ActivL Artificial Disc — FDA approved for single level L4-S1 (2018)
    ProDisc-L (device)ProDisc-L Total Disc Replacement — FDA approved for single or two contiguous levels L3-S1 (2017; 2020 supplement)
    Charite (device)Charite Artificial Disc — FDA approved 2004; withdrawn 1/5/2012 (single level L4-S1)
    FlexiCore (device)FlexiCore Artificial Disc — not currently approved/marketed in U.S. (IDE/completed trial)
    INMOTION (device)INMOTION lumbar artificial disc — not currently marketed in U.S.
    Kineflex-L (device)Kineflex-L — device not marketed in U.S.; advisory committee meeting canceled
    Maverick (device)Maverick artificial disc — not marketed in U.S. due to litigation
    Thoracic-level devicesmixedNot Covered
    Thoracic devicesNo FDA-approved devices for thoracic levels
    Codes mentionedmixed
    No codes listed
    Codes mentionedmixed
    No codes listed
    Devices mentionedmixed
    ProdiscLLumbar artificial intervertebral disc device marketed in U.S.
    activLLumbar artificial intervertebral disc device marketed in U.S.
    Procedure CPT/HCPCS codes listed in policyCPT
    0095TRemoval of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure).
    0098TRevision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure).
    0164TRemoval of total disc arthroplasty, anterior approach, lumbar, each additional interspace.
    0165TRevision of total disc arthroplasty, anterior approach, lumbar, each additional interspace.
    22856Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection), single interspace, cervical.
    22857Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); single interspace, lumbar.
    22858Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure).
    22860Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure).
    22861Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical.
    22862Revision including replacement of total disc arthroplasty (artificial disc) anterior approach, single interspace; lumbar.
    1–10 of 13
    1/2
    Age — typical age range specified
    Age range18–60 years
    Cervical conservative therapy duration — minimum duration
    Minimum cervical conservative therapyAt least 6 weeks of conservative nonoperative treatment including active pain management with pharmacotherapy addressing neuropathic pain and physical therapy
    Lumbar conservative therapy duration — minimum duration
    Minimum lumbar conservative therapyAt least 6 months of consistent nonoperative treatment including pharmacotherapy and formal physical therapy
    Osteopenia/osteoporosis contraindication — T-score threshold
    Osteopenia/osteoporosis contraindicationDEXA T-score ≤ -1.0 (listed as contraindication/exclusion)
    Failed conservative therapy duration — cervical vs lumbar timelines
    Failed conservative therapy — cervical timelineCommonly requires failure of at least 6 weeks prior to cervical disc implantation
    Failed conservative therapy — lumbar timelineCommonly requires failure of at least 6 months prior to lumbar disc implantation (device-specific)
    Conservative treatment duration — at least 6 months cited in device approvals
    Conservative treatment duration cited in device approvalsDevice approvals commonly cite failure of at least 6 months of conservative treatment prior to lumbar implantation
    Cervical device labeling noteMany cervical devices require failure of at least 6 weeks of nonoperative care per labeling
    NDI improvement threshold used in trials — >15 points (FDA success criterion)
    NDI improvement threshold used in trials (FDA success criterion)>15-point improvement in Neck Disability Index (NDI)
    NDI improvement threshold — ≥15-point improvement in NDI
    NDI trial threshold≥15-point improvement in NDI used in pivotal trial overall success definitions
    Minimal clinically important difference (ODI) — MDD/MCID ranges
    ODI minimal detectable/clinically important differenceMDD: 8–10 points; MCID often cited as ~15 points (30 percentage points)
    Visual analog scale (pain) — MDD thresholds
    Visual analog scale (pain) MDDMinimal detectable difference: ~2 points for back pain and ~5 points for leg pain on a 0–10 scale
    Oswestry Disability Index (ODI) — trial thresholds reported (ODI ≥30 or ≥40)
    ODI trial thresholds reportedTrial eligibility thresholds reported as ODI ≥30 in some trials and ODI ≥40 in the 2-level ProDisc-L trial
    Conservative therapy duration — minimum commonly reported ≥6 months
    Conservative therapy duration commonly reportedMinimum conservative therapy commonly reported as ≥6 months (particularly for lumbar trials/devices)

    Preauthorization, Documentation, and Operational Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for disc arthroplasty. Requests must document the specific FDA‑approved device (model/name) and that the planned vertebral level(s) match the device labeling. Provide surgeon evaluation notes and complete clinical documentation as listed below when submitting for authorization.

    • Prior authorization required per payer coding table and device-specific indications.
    • Document device model/name and FDA approval status; verify levels to be treated align with device labeling.
    • Surgeon must have personally evaluated the patient prior to authorization request (exceptions: malignancy, trauma, infection, or rapidly progressive neurologic symptoms).
    Documentation Required

    Prior Conservative Therapy and Baseline ODI

    When requesting authorization for cervical or lumbar disc arthroplasty, include evidence of failed conservative therapy and baseline functional scores. For lumbar devices, trials typically required at least 6 months of multimodal nonoperative care and an ODI threshold used in pivotal studies; for cervical devices, at least 6 weeks of conservative care is expected.

    • Cervical: documentation of ≥6 weeks of conservative nonoperative treatment including active pain management, pharmacotherapy addressing neuropathic pain, and physical therapy (exceptions apply for severe/rapidly progressive neurologic compromise).
    • Lumbar: documentation of ≥6 months of consistent nonoperative multimodal treatment (physical therapy, pharmacotherapy ± injections, rehab) and documentation of functional impairment; include baseline Oswestry Disability Index (ODI) score (trials often required ODI ≥30–40).
    • If conservative therapy was contraindicated or impossible (e.g., immediate surgical need), document rationale.
    Prior Authorization

    Evidence Submission Recommended with Authorization

    Submit supporting clinical evidence with the authorization request when applicable. Randomized controlled trial data, pivotal IDE study summaries, registry or long‑term cohort outcome data (ODI, VAS, complications, revision rates) and device post‑approval study results strengthen evaluation. If long‑term or comparative evidence is limited for a device, note this in the submission.

    • Provide pivotal trial summaries (RCT or IDE) and key outcome metrics (NDI/ODI changes, VAS, reoperation rates).
    • Include registry or prospective cohort follow‑up (functional scores, complications, revisions) if available.
    • If device lacks RCTs vs fusion or conservative care (e.g., activL lacked RCTs vs fusion in some reports), explicitly state evidence gaps.
    Denial Risk

    Documentation‑Based Denial Risks and Evidence Limitations

    Absence of required documentation or evidence gaps may lead to denial. Specific denial risks include missing surgeon preoperative evaluation, failure to document adequate conservative therapy or baseline ODI, use of a device not FDA‑approved for the intended vertebral level(s), and insufficient evidence of device safety/effectiveness for the indication.

    • Missing documentation that the requesting surgeon personally evaluated the patient may trigger denial.
    • Claims for devices not approved for the indicated spinal level or not FDA‑approved may be denied.
    • Lack of documentation of failed conservative therapy and baseline functional scores (e.g., ODI) increases denial risk.
    • Evidence limitations (limited RCTs, short follow‑up) can contribute to a coverage denial or request for more evidence.
    Denial Risk

    Tobacco Use Contraindication

    Tobacco use is a contraindication for disc arthroplasty if used within the prior 4 weeks. Document tobacco status; if tobacco use is present, encourage and document cessation efforts. Active recent tobacco use may be a reason to defer or deny authorization.

    • Tobacco use (cigarettes, cigars, pipes, vaping, smokeless tobacco) within the previous four weeks is a contraindication.
    • Document tobacco cessation counseling and any plan for abstinence prior to surgery.
    Documentation Required

    Population, Setting, and Patient Selection Requirements

    Patient selection must align with trial populations and guideline recommendations. Devices and procedures should be performed in appropriate specialist settings with multidisciplinary input. Cases outside recommended populations (e.g., scoliosis, >Grade I spondylolisthesis, significant instability, chronic predominant radiculopathy, severe facet arthropathy, age outside device labeling) are typically excluded and may be denied.

    • NASS and trial populations excluded patients with scoliosis, spondylolisthesis > Grade I, instability, or predominant chronic radiculopathy.
    • NICE recommends procedures be performed in specialist units; multidisciplinary team selection is encouraged for lumbar arthroplasty.
    • Age and other device‑specific contraindications (e.g., osteoporosis/DEXA T‑score thresholds) must be satisfied.
    Step Therapy

    Step Therapy: None Specified in Excerpt

    No explicit step‑therapy or formal step‑limit requirements for disc arthroplasty are specified in this excerpt. Ensure conservative therapy details and duration are documented as described rather than relying on a separate step‑therapy prior authorization pathway.

    • Policy does not define a separate step‑therapy program; document required conservative care durations (cervical ≥6 weeks, lumbar ≥6 months) and modalities instead.
    Billing Rule

    Coding and Claim Reporting Requirement

    Coding: report provider services using appropriate CPT, HCPCS, Revenue, and ICD diagnosis codes. Claims may be denied or delayed if services are not reported with appropriate codes.

    • Use the payer Codes table and standard coding guidance when submitting authorization and claims.
    • Ensure device and procedure coding align with the authorization documentation to avoid coding‑based denials.

    Clinical Background and Evidence Summary

    Cervical disc arthroplasty is presented as an alternative to anterior cervical discectomy and fusion for symptomatic cervical degenerative disc disease. Randomized trials summarized in the policy have demonstrated noninferiority of several cervical devices to ACDF, and some devices show sustained benefits in mid‑ to long‑term follow‑up for selected patients.

    The document segments cited do not contain additional explicit coverage exclusions beyond the investigational and contraindication lists; absence of a separate exclusion statement in these chunks is noted to contextualize the background and evidence summaries.

    In the provided excerpts there are no explicit statements that label particular services or patient groups as universally not medically necessary. The document uses investigational designations and device‑label contraindications to indicate unsupported uses; therefore an explicit ‘not medically necessary’ list is not present in these specific chunks.

    Key Definitions and Measures

    Artificial intervertebral disc / total disc replacement — definition
    DefinitionA prosthetic device implanted at a cervical or lumbar intervertebral level intended to replace the diseased disc and preserve motion as an alternative to spinal fusion
    Degenerative disc disease (cervical/lumbar) — definition
    DefinitionDeterioration of intervertebral discs causing symptoms (radiculopathy, myelopathy, or discogenic back pain) typically confirmed by imaging and clinical correlation
    FDA-approved device — definition
    DefinitionA prosthetic disc that has received U.S. FDA premarket approval for specific vertebral levels and indications (may include postmarketing study requirements)
    Degenerative disc disease (DDD) — definition
    DefinitionDiscogenic back pain with degeneration of the disc confirmed by patient history and radiographs; device approvals reference DDD as the indication
    Neck Disability Index (NDI) — definition
    DefinitionNeck Disability Index (NDI): validated 10-item instrument measuring neck pain–related disability; scores range 0%–100% with lower scores indicating less disability
    ACDF — definition
    DefinitionACDF: anterior cervical discectomy and fusion (surgical comparator)
    CDA — definition
    DefinitionCDA: cervical disc arthroplasty (artificial cervical disc replacement)
    NDI — definition (duplicate measure entry)
    DefinitionNDI: Neck Disability Index, a 10-item patient-reported outcome measuring neck-related disability
    SSED — definition (FDA Summary of Safety and Effectiveness)
    DefinitionSSED: FDA Summary of Safety and Effectiveness — document supporting device approval
    Overall success — definition used in pivotal trials (NDI ≥15, neurologic function, etc.)
    Definition of overall success in trialsComposite 'overall success' typically required ≥15-point improvement in NDI, maintenance or improvement in neurologic function, and absence of serious implant/procedure-related adverse events or supplemental surgery
    FDA SSED — definition
    DefinitionFDA SSED: U.S. Food and Drug Administration Summary of Safety and Effectiveness data used to support device approval
    Discogenic back pain with degeneration confirmed by history and radiographs — definition
    DefinitionDiscogenic back pain with degenerative changes confirmed by patient history and radiographs (radiographic signs may include reduced disc height, Modic changes, high-intensity zone, or dark nucleus pulposus)
    ODI — definition and role as patient-reported outcome
    DefinitionOswestry Disability Index (ODI): patient-reported measure of functional disability related to back conditions; 10 items scored to produce 0–100% scale
    DDD — definition (duplicate concept)
    DefinitionDegenerative disc disease (DDD): deterioration of intervertebral discs causing symptomatic pain attributed to the degenerated disc
    IDE — Investigational Device Exemption definition
    DefinitionIDE: Investigational Device Exemption — FDA-regulated trials to evaluate devices in controlled settings prior to/after approval
    ODI — definition (trial measure)
    DefinitionODI: Oswestry Disability Index — functional status measure commonly used as a primary outcome in lumbar trials
    VAS — definition
    DefinitionVAS: Visual Analog Scale — patient-reported pain measure (for back and leg pain) typically 0–10 or 0–100 scale
    RCT — definition
    DefinitionRCT: Randomized controlled trial — design used for pivotal device evaluations
    Lumbar artificial disc replacement (ADR) — definition and typical levels
    DefinitionLumbar ADR: surgical replacement of a single lumbar intervertebral disc (commonly L3-L4, L4-L5, or L5-S1) intended to preserve motion; devices approved for specific levels (e.g., ActivL L4–S1; ProDisc-L L3–S1)
    Total disc arthroplasty / artificial disc — definition of surgical approach
    DefinitionTotal disc arthroplasty / artificial disc: surgical implantation of an artificial intervertebral disc via an anterior approach including associated discectomy and end-plate preparation

    Policy History and References

    2025-06Annual reviewLatest

    Policy renewed following annual review.

    2024-06Annual review

    Policy revised after annual review.

    2023-06Annual review

    Policy renewed following annual review.

    2023-03Interim/annual review

    Policy revised following a March review (record lists both March 2023 review and revision).

    2022-03Annual review

    Policy revised following annual review.

    2021-03Annual review

    Policy revised following annual review.

    2020-03Annual review

    Policy revised following annual review.

    2019-03Annual review

    Policy revised following annual review.

    2018-03Annual review

    Policy revised following annual review.

    2017-03Annual review

    Policy revised following annual review.

    2016-04Annual review

    Policy revised following annual review in April 2016.

    2015-08Interim review

    Policy revised after an interim review in August 2015.

    2015-05Annual review

    Policy revised following annual review in May 2015.

    2015-02Annual review

    Policy revised following annual review in February 2015.

    2014-02Annual review

    Policy renewed following annual review in February 2014.

    2013-03Annual review

    Policy renewed following annual review in March 2013.

    2012-03Annual review

    Policy renewed following annual review in March 2012.

    2011-04Annual review

    Policy renewed following annual review in April 2011.

    Reference and FDA document access dates cited within the policy span multiple years through 2025. Several FDA Summary of Safety and Effectiveness Data (SSED) and peer‑reviewed trial publications are referenced with access dates in 2024–2025, indicating the evidence base and regulatory status were reviewed up to early 2025.